4D MOLECULAR THERAPEUTICS, INC.

(FDMT)
  Report
Delayed Nasdaq  -  04:00 2022-07-01 pm EDT
6.960 USD   -0.29%
06/244D MOLECULAR THERAPEUTICS, INC.(NASDAQGS : FDMT) dropped from Russell 2500 Growth Index
CI
06/244D MOLECULAR THERAPEUTICS, INC.(NASDAQGS : FDMT) dropped from Russell 3000E Growth Index
CI
06/244D MOLECULAR THERAPEUTICS, INC.(NASDAQGS : FDMT) dropped from Russell Microcap Growth Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

4D Molecular Therapeutics to Participate in the BofA Securities 2022 Healthcare Conference

05/05/2022 | 04:02pm EDT

EMERYVILLE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that management will participate in the 2022 Bank of America Healthcare Conference on Tuesday, May 10th. Details of the fireside chat are as follows:

Event: BofA Securities 2022 Healthcare Conference

Date & Time: Tuesday, May 10, 2022 at 8:40 a.m. PT

A live audio webcast of the presentation will be available by visiting the “Investors & Media” section of the 4DMT website at www.4dmoleculartherapeutics.com. A replay of the webcast will be available for at least two weeks following the live event.

About 4DMT

4DMT is a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines. 4DMT seeks to unlock the full potential of genetic medicines using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent targeted and evolved vectors for use in our products. The company is initially focused on five clinical-stage products in three therapeutic areas for both rare and large market diseases: ophthalmology, cardiology (including Fabry disease) and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered at relatively low doses through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. The five 4DMT product candidates in clinical development are: 4D-310 for Fabry disease, 4D-150 for wet AMD, 4D-125 for XLRP, 4D-110 for choroideremia and 4D-710 for cystic fibrosis.

Contacts:

Media:

Ingrid Mezo
Canale Communications
ingrid.mezo@canalecomm.com

Investors:

Mike Zanoni
VP, Investor Relations
mzanoni@4dmt.com


Primary Logo

Source: 4D Molecular Therapeutics, Inc.

2022 GlobeNewswire, Inc., source Press Releases

All news about 4D MOLECULAR THERAPEUTICS, INC.
06/244D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) dropped from Russell 2500 Growth Index
CI
06/244D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) dropped from Russell 3000E Growth Index
CI
06/244D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) dropped from Russell Microcap Growth Index
CI
06/244D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) dropped from Russell 3000 Growth Index
CI
06/244D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) dropped from Russell Small Cap Comp Growth In..
CI
06/244D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) dropped from Russell 2000 Growth Index
CI
06/22Jefferies Starts 4D Molecular Therapeutics at Buy With $22 Price Target
MT
06/214D MOLECULAR THERAPEUTICS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fisc..
AQ
06/214D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) dropped from S&P Biotechnology Select Industr..
CI
06/15TRANSCRIPT : 4D Molecular Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global ..
CI
More news
Analyst Recommendations on 4D MOLECULAR THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 4,98 M - -
Net income 2022 -100 M - -
Net cash 2022 47,1 M - -
P/E ratio 2022 -2,22x
Yield 2022 -
Capitalization 225 M 225 M -
EV / Sales 2022 35,7x
EV / Sales 2023 25,9x
Nbr of Employees 137
Free-Float 88,4%
Chart 4D MOLECULAR THERAPEUTICS, INC.
Duration : Period :
4D Molecular Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends 4D MOLECULAR THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 6,96 $
Average target price 21,20 $
Spread / Average Target 205%
EPS Revisions
Managers and Directors
David H. Kirn President, Chief Executive Officer & Director
August J. Moretti Chief Financial Officer
John F. Milligan Executive Chairman
Fred Kamal Chief Technical Officer
Peter Francis SVP-Clinical Translational R&D
Sector and Competitors
1st jan.Capi. (M$)
4D MOLECULAR THERAPEUTICS, INC.-68.28%225
MODERNA, INC.-40.96%59 644
IQVIA HOLDINGS INC.-23.78%40 704
LONZA GROUP AG-31.09%40 503
SEAGEN INC.16.50%33 154
CELLTRION, INC.-9.34%19 151